Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP15 | Q460N3 | 4/20 | 0.54 |
| ▸ | PARP10 | Q53GL7 | 4/20 | 0.54 |
| ▸ | PARP2 | Q9UGN5 | 2/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | EGFR | P00533 | 2/20 | 0.45 |
| ▸ | HRH2 | P25021 | 1/20 | 0.44 |
| ▸ | HRH1 | P35367 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | GLA | P06280 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10148245 | 0.90 | PARP15 (0.54) | PARP15PARP10PARP2MAPTHPGD | |
| SCHEMBL2087536 | 0.86 | PARP15 (0.70) | PARP15PARP10PARP2MAPTHPGD | |
| SCHEMBL10184937 | 0.84 | TSHR (0.49) | PARP15PARP10PARP2MAPTHPGD | |
| SCHEMBL10186108 | 0.81 | PARP15 (0.48) | PARP15PARP10PARP2MAPTHPGD | |
| SCHEMBL4117982 | 0.80 | PARP10 (0.71) | PARP15PARP10PARP2MAPTHPGD | |
| SCHEMBL6958286 | 0.79 | PARP10 (0.72) | PARP15PARP10PARP2MAPTKMT2A | |
| SCHEMBL7733823 | 0.76 | PARP15 (0.66) | PARP15PARP10PARP2MAPTHPGD | |
| SCHEMBL17150475 | 0.76 | PARP15 (0.56) | PARP15PARP10PARP2MAPTL3MBTL1 | |
| SCHEMBL7737448 | 0.76 | PARP10 (0.66) | PARP15PARP10PARP2MAPTKMT2A | |
| SCHEMBL19405797 | 0.76 | FFAR1 (0.48) | MAPTKMT2AMEN1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120046292-A1 | DIACYLETHYLENEDIAMINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2012-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120046292-A1 | DIACYLETHYLENEDIAMINE COMPOUND | DGAT1, DGAT2, DIMT1 | PARP15 1911/4885PARP10 1704/4885PARP2 3367/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.